• Johnson & Johnson disclosed Phase 3 MonumenTAL-3 results already presented at the 2026 EHA meeting, with simultaneous publication in The New England Journal of Medicine.
• The TALVEY and DARZALEX FASPRO combinations, with or without pomalidomide, delayed disease worsening and extended survival versus a standard daratumumab-based regimen.
• Results support moving the GPRC5D-targeting bispecific approach into earlier relapsed or refractory multiple myeloma treatment, a potential expansion of addressable use.
• Safety was broadly consistent with known profiles; severe infections were lower in the two-drug arm, while cytokine release syndrome was mostly low grade.
• Regulatory filings were submitted to the FDA and EMA seeking use of the combination after at least one prior line of therapy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606130633PR_NEWS_USPR_____NY78620) on June 13, 2026, and is solely responsible for the information contained therein.